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Abstract
Background: Inflammatory arthritis leads to work disability, absenteeism and presenteeism (i.e. at-work productivity
loss) at high cost to individuals, employers and society. A trial of job retention vocational rehabilitation (VR) in the
United States identified this helped people keep working. The effectiveness of this VR in countries with different
socioeconomic policies and conditions, and its impact on absenteeism, presenteeism and health, are unknown.
This feasibility study tested the acceptability of this VR, modified for the United Kingdom, compared to written
advice about managing work problems. To help plan a randomized controlled trial, we tested screening,
recruitment, intervention delivery, response rates, applicability of the control intervention and identified the
relevant primary outcome.
Methods: A feasibility randomized controlled trial with rheumatoid, psoriatic or inflammatory arthritis patients
randomized to receive either job retention VR or written information only (the WORK-IA trial). Following three
days VR training, rheumatology occupational therapists provided individualised VR on a one to one basis. VR
included work assessment, activity diaries and action planning, and (as applicable) arthritis self-management
in the workplace, ergonomics, fatigue and stress management, orthoses, employment rights and support
services, assistive technology, work modifications, psychological and disclosure support, workplace visits and
employer liaison.
Results: Fifty five (10%) people were recruited from 539 screened. Follow-up response rates were acceptable
at 80%. VR was delivered with fidelity. VR was more acceptable than written advice only (7.8 versus 6.7). VR
took on average 4 h at a cost of £135 per person. Outcome assessment indicated VR was better than written
advice in reducing presenteeism (Work Limitations Questionnaire (WLQ) change score mean: VR = −12.4 (SD
13.2); control = −2.5 (SD 15.9), absenteeism, perceived risk of job loss and improving pain and health status,
indicating proof of concept. The preferred primary outcome measure was the WLQ, a presenteeism measure.
Conclusions: This brief job retention VR is a credible and acceptable intervention for people with
inflammatory arthritis with concerns about continuing to work due to arthritis.
Trial registration: ISRCTN 76777720. Registered 21.9.12.
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Background
Work problems are common in people with inflamma-
tory arthritis. A third of employed people with rheuma-
toid arthritis (RA) stop working within three years of
diagnosis due to arthritis (i.e. become work disabled)
and 50% within 10 years [1]. Before this, people experi-
ence work instability, i.e. a mismatch between abilities
and job demands which threatens employment [2]. This
is associated with increased: absenteeism, as employed
people with RA average 40 days sick leave per year com-
pared to the 6.5 days United Kingdom (UK) average [1];
and presenteeism (i.e. reduced at-work productivity),
with 24% of working time lost due to health problems
[3]. Once unemployed, people with RA are unlikely to
return to work [4]. Many factors influence work instabil-
ity and disability including: greater pain, hand pain and
fatigue; unadapted work environments and equipment;
physically demanding jobs; poor work self-efficacy; job
strain; and limited use of self-management strategies [4–8].
Job retention vocational rehabilitation (VR) has the po-
tential to prevent or postpone work disability through
modifying such factors. For example, those with work-
place ergonomic modifications are 2.5 times less likely
to stop work [6]. VR should be provided early, when
work instability develops. However, many with arthritis
lack access to VR.
A recent systematic review identified only two success-
ful randomized controlled trials (RCTs) of job retention
VR in arthritis [9]. These demonstrated: at 4.5 years, sig-
nificant reductions in job loss (n = 242) [10]; and at six
months, improvements in work instability, work satisfac-
tion, pain and self-perceived ability to manage work
(n = 32) [11]. Allaire et al. [10] evaluated a brief (three
hour) intervention delivered by rehabilitation counsel-
lors in the United States of America (USA), including
work assessment and problem-solving participants’ pri-
ority difficulties. It is unclear if similar results would
occur in the UK, with a different social security system,
employment law and rehabilitation services. Macedo
et al. [11], in a UK study, evaluated a comprehensive
functional, work and psychosocial assessment, followed
by six to eight sessions (30–120 min each) of individua-
lised VR and comprehensive occupational therapy, in-
cluding a group patient education programme. The drive
for efficiency in the UK National Health Service (NHS)
means many therapy services now provide brief inter-
ventions and group education provision is patchy.
Thus a longer intervention may not be feasible. Nei-
ther study measured effects on absenteeism or pres-
enteeism. These findings suggest brief job retention
VR, based on that developed in the USA [10], deliv-
ered by occupational therapists with job retention VR
training as part of Rheumatology NHS services, could
be effective in the UK.
The aims of this study were to determine the feasibility
of conducting a full RCT of job retention VR for
employed people with inflammatory arthritis, specifically
RA, undifferentiated inflammatory arthritis (IA) and
psoriatic arthritis (PsA), as these are common conditions
seen in Rheumatology departments. We investigated:
screening and recruitment processes, study uptake, barriers
to participation and retention rates; treatment fidelity; feasi-
bility of assessment methods (proportion of missing data);
the most feasible primary work outcome measure (time to
job loss; employment status; absenteeism; or presenteeism);
estimate a sample size for a definitive RCT; proof of
principle by describing any changes in work and health out-
comes; and the feasibility of Rheumatology occupational
therapists delivering the VR.
Methods
Design and setting
We conducted a feasibility RCT comparing job retention
VR (plus work self-help information) with work self-help
information only in six Rheumatology occupational ther-
apy services in England from November 2011 to July
2013. The trial was managed by Nottingham Clinical
Trials Unit (CTU). Ethics approval was granted by the
National Research Ethics Committee East Midlands
(Nottingham 1:11/EM/0103) and University of Salford
Ethics Panel.
This was a three-year study. The recruitment period
was seven to ten months (i.e. varying between sites).
This was reduced from 12 months because of delays in
study approvals and restricted availability of research fa-
cilitators (i.e. research nurses and others employed by
National Institute of Health Research (NIHR) Clinical
Research Networks (CRN) and NHS Trust Research and
Development departments to support study recruitment
in the NHS. They are not part of the research project
team and thus not supervised by the trial manager). As a
result, the funder (Arthritis Research UK) recommended
that the follow-up period was reduced from 12 to nine
months, in order to maximise the recruitment time
available. The protocol was accordingly amended to con-
duct follow-up at nine months.
Eligibility criteria
Participants were eligible if they were: 18 years of age or
over; diagnosed with RA, PsA or undifferentiated IA (i.e.
persistent symmetrical synovitis without any other
known cause, but the person does not yet meet diagnos-
tic criteria for RA); in paid work (full- or part-time); able
to read, write and understand English; and willing to re-
ceive VR. We also tested which criterion best established
need for VR: scoring ≥10 on the RA-Work Instability
Scale (RA-WIS) [11], (i.e. a score indicating medium to
high risk of work instability and need for VR [2]) or
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stating “Yes” to “Do you have any concerns about your
health affecting your ability to work over the next few
years?” [10].
Exclusion criteria were: on extended sick leave (i.e.
>three months) or unemployed (including not normally
in paid employment or student); within the next
12 months, either planning to retire or take early retire-
ment (through choice or ill health), move out of area or
expecting joint replacement surgery; or already receiving
or awaiting VR services.
Recruitment procedures
NIHR CRN support for screening and recruitment was
agreed prior to trial start. Screening was planned to be
conducted by research facilitators in at least two
Rheumatology out-patient clinic sessions per week at
each site. If possible, a week before clinics, the health-
care team identified working age patients with RA, PsA
or IA on clinic lists and research facilitators mailed out
study information packs. If not, the health care team
identified patients during clinic appointments and intro-
duced them to the research facilitator. Research facilita-
tors then screened patients in clinic. For those eligible
and willing, research facilitators explained the study, ob-
tained written consent, recorded baseline demographic
data and the participant either completed the baseline
questionnaire in clinic or later at home and mailed it
back to the research facilitator. Research facilitators also
explained how to complete a monthly calendar reporting
work status and sickness absence (see Outcome Mea-
sures: absenteeism). For those receiving study informa-
tion in advance, research facilitators consented patients
that day in clinic. For those referred in clinic, eligible
patients were allowed at least 48 h to consider participa-
tion. These patients were then telephoned by research
facilitators to complete consent via telephone and mail
and to remind about baseline questionnaire return.
Randomisation and allocation concealment
Following baseline questionnaire return, research facilita-
tors randomized participants using a web-based random-
isation system to receive either work self-help information
only (control group) or VR plus work self-help informa-
tion (intervention group). The randomization sequence
was created using Stata 9.09.2 (Ralloc function by Philip
Ryan v3.3.2) statistical software and was stratified by site,
to ensure even occupational therapists’ workloads, with a
1:1 allocation using permuted blocks of randomly varying
sizes. Treatment assignment was by the web-based ran-
domisation system managed by Nottingham CTU. Follow-
ing randomisation, research facilitators mailed the
participant’s screening checklist, demographic record and
baseline questionnaire to the trial manager, who then
mailed the participant the work self-help information.
Intervention group participants’ contact details were sent
to the treating occupational therapist by an automatically
generated e-mail from the randomization system. The
research facilitator, trial manager, and research staff col-
lecting, entering and analysing data were blinded to group
allocation. Blinding of participants and therapists to trial
arm was not possible. Occupational therapists were asked
to continue with their usual VR practice with non-trial
participants (see below).
Control group
NHS “usual care” for work problems for most people
with RA, PsA or IA is limited. Referral to occupational
therapy for VR is often patchy or non-existent. VR
(when provided) consists of, on average 45 [IQR 30–90]
minutes work advice (without a structured work assess-
ment), provision of work advice booklets and signpost-
ing to other services [12, 13]. Control participants
therefore received written self-help work information
only, i.e. a similar control to that used by Allaire et al.
[10]. This consisted of a cover letter, self-help flowchart
and two work advice booklets [14, 15]: see Additional
file 1). Participants continued to receive usual Rheuma-
tology care (i.e. regular out-patient appointments, pre-
scribed medication, and referral by Consultants to
therapy services as necessary).
Intervention group
Intervention group participants also received written
work self-help information and usual care. Treating oc-
cupational therapists received three days VR training
[12]. Participants were seen within four weeks of referral.
Direct VR consisted of up to 4.5 h of 1:1 meetings, start-
ing with a structured work interview and ending with a
telephone review. Up to 1.5 h extra contact was also
possible. We planned VR to be longer than in Allaire
et al.’s trial [10] as: therapists were providing this VR for
the first time; Allaire et al. had recommended extra time
for complex cases and a telephone review [10]; and we
included optional work site visits. We paid for up to
10 h occupational therapy time (plus mileage costs for
any visits) per VR group participant. This included both
direct and indirect VR (i.e. non-contact time when ther-
apists: completed treatment notes; identified solutions
for work problems; liaised with team members, other
agencies and employers; and travel time).
Meetings were at mutually agreed times (often early or
late in the day to fit around participants’ work commit-
ments) and locations (the occupational therapy department,
participant’s home or workplace) spread over two to four
months. The intervention started with a structured work
interview and job discussion (i.e. an assessment of the
person’s job, roles and responsibilities in relation to their
condition, disease severity and activity limitations) and
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detailed assessment of work barriers. This was conducted
using the UK Work Experience Survey-Rheumatic Condi-
tions (WES-RC) [16–19]. This was followed by mutually
agreeing priority work problems, action planning, and
then a tailored, individualised programme including self-
management at work, job accommodations, employment
rights information and other strategies as relevant. Partici-
pants were offered a work site visit, if this was identified
as relevant to their needs. VR also emphasised partici-
pants’ responsibilities in liaising with employers and
included role play, as necessary, to enhance confidence
requesting job accommodations (See Additional file 1).
Treatment fidelity
The WORK-IA VR Resource Manual was provided to
support VR delivery. (See Additional file 1) [20]. Monitoring
visits assessed treatment fidelity conducting the WES-RC,
problem identification and treatment planning. Addition-
ally, a random six WES-RCs and treatment notes were
reviewed for problem identification and matching treat-
ment to problems.
Outcome measures
Follow-up data was collected using a questionnaire book-
let at six and nine months, mailed by the trial manager.
After two weeks, if not returned, a telephone reminder
was given and a second questionnaire mailed, if necessary.
The following outcomes and information were collected
at each time point (baseline, six and nine months):
Demographic and work data: age, gender, condition
duration, marital and living status (at baseline only);
medication regimen; current job(s); years in current main
job; whether disclosed arthritis to employer and/or work
colleagues; and number of normal working hours.
Work measures
Employment status: whether in full- or part-time work,
on long term sick leave, or stopped working (with date
when stopped and reason).
Presenteeism: these measures evaluate the effect of a
condition on the quality or quantity of work productivity
[21]. Three measures evaluated different aspects:
i) RA- Work Instability Scale (RA-WIS): 23 true/false
items measuring, at present, the degree of mismatch
between functional abilities and workplace demands [2].
ii) Work Activities Limitations Scale (WALS): 12 items
(time frame unspecified) indicating degree of
difficulty performing physical work activities, time,
mental and output demands (0 = no difficulty;
3 = unable to do), with additional items for whether
help or equipment are used for each [22].
iii)The Work Limitations Questionnaire (WLQ): 25
items, indicating the amount of time, in the last two
weeks, a person was limited in: physical work
demands, time demands, mental-interpersonal
demands and output demands. The four sub-scale
scores and Summed score (i.e. average of the four
sub-scales) range from 0 to 100%. A percentage
Productivity Loss score can also be calculated [23].
Work self-efficacy: confidence in ability to continue
working with arthritis; and ability to manage arthritis at
work (0–10 numeric rating scales (NRS)).
Satisfaction with work rehabilitation advice received
(0–10 NRS at six months only).
Health related outcomes
SF-12v2 Health Survey: 12 items, assessed over the last four
weeks, scored as physical and mental health sub-scales [24].
Multi-dimensional Health Assessment Questionnaire
(HAQ): the modified HAQ (eight activity limitation items);
psychological status HAQ (four items); pain, fatigue and a
global rating of health measured using 100 mm Visual
Analogue Scales (VAS), assessed over the last week [25].
Hand/ wrist pain: pain in the last week during moder-
ate activity (100 mm VAS).
Euroqol five dimensions questionnaire (EQ5D): meas-
uring quality of life [26].
Health economic outcomes
A self-report measure was resource use questionnaire (use
of health resources, health-related transport costs, personal
and domestic care support, work support and adaptations).
Work status measures
In addition to the questionnaire booklet, participants
filled out a monthly tear-off calendar, to record their
work status each day (i.e. performed paid work, unable
to perform paid work due to arthritis, unable to perform
paid work due to other reasons, day off ). This was modi-
fied from Part 1 of the Health and Labour Questionnaire
[27]. Participants were asked to return each page at
month end in Freepost envelopes to the trial manager. If
not returned within two weeks, the trial manager tele-
phoned to remind return. The following work outcomes
were derived from the monthly calendar:
Time to temporary or permanent job loss (days): re-
cording on which date their contract ended, if they
stopped working and, if a new job was obtained, their
contract started.
Absenteeism: over nine months, the number of days
sickness absence attributable to either arthritis or other
causes (e.g. common ailments), not including days not
normally worked.
Participants were not telephoned to obtain missing data
from returned questionnaires or minimal datasets from
non-responders, apart from for the absenteeism measure.
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VR provision
Therapists completed a VR Treatment Record of: duration
of treatment contact for direct VR (i.e. with participant)
and indirect VR (e.g. administration, making referrals,
sourcing information, treatment planning, travel time for
home/ work visits); treatment location; and travel mileage.
Sample size
A statistically based sample size estimate was inapplicable
for this feasibility study. Randomising 100 participants
would permit estimation of the percentage of overall
drop-outs to +/− 10% points at most, with 95% confi-
dence. Drop-outs were considered those who did not at-
tend VR or did not return follow-up questionnaires.
Statistical analyses
Analyses were mainly descriptive in order to determine
if a definitive RCT is feasible. Recruitment and retention
rates were summarised descriptively. For each outcome
measure and trial arm, the proportion of missing data
was described and the outcome at follow-up summarised
(using means and standard deviations for continuous
measures or frequency counts and percentages for cat-
egorical data). Where, applicable, change from baseline
was also summarised and effect sizes were calculated) as
mean change/standard deviation at baseline) to compare
the internal responsiveness of outcomes. An effect size
of 0.2 is interpreted as small, 0.5 medium and 0.8 large
effect sizes [28]. All analyses were according to random-
isation allocation. Quality of Adjusted Life Years
(QALYs) were calculated using EQ5D. VR duration and
costs were identified from the VR Treatment Records
and costed using published data [29].
Results
Project schedule, screening, recruitment and retention rates
Ethics approvals were obtained to schedule. Sites recruited
varyingly between November 2011 and September 2012
and actively recruited for 6.5 months (1QR 5–7) (i.e. 54%
of the original 12 months planned time). This was because
Local NHS Trust Research and Development department
(R&D) approvals were delayed and took until month 14 at
five sites and month 17 at one site. Five sites were re-
scheduled to open for ten and one for seven months.
Average time to recruit the first patient was 14 weeks
(IQR 10.5–17.25) as, for the first three to four months,
there was little or no research facilitator availability at four
sites. At six months, two sites closed: research facilitator
support was withdrawn at one and the only occupational
therapist went on long-term sick leave at the other.
The flow of participants is shown in Fig. 1. Of the 539
screened, 37% (n = 199) were eligible. Of these, 28% of
those eligible (n = 55; 10% overall) consented. At screen-
ing, most had RA-WIS scores ≥10 (i.e. moderate to high
risk of work disability). Only six (11%) had scores <10
but answered “yes” to concerns about continuing work-
ing with arthritis. Their average RA-WIS score at
screening was 5.5 (SD 2.7) but rose to 7.8 (SD3.7) at
baseline, as three now reported RA-WIS scores ≥10. The
two intervention group participants with scores <10 at
screening, had multiple problems identified in the WES-
RC, indicating VR was applicable. Given most people
with concerns had RA-WIS scores ≥10, and those scor-
ing <10 at screening had scores close to or ≥10 at base-
line, using the concerns criterion is applicable for a
future trial. Most participants completed baseline ques-
tionnaires at home, with only 10 choosing to do so in
clinic. Within the two groups, 1/26 in the control group
was incorrectly referred to occupational therapy by the
CTU and received VR; and 4/29 in the intervention
group did not complete VR (one was not referred by the
CTU; one had already retired early; one did not want
VR; and one could not be contacted). By six months,
one person in the intervention group withdrew.
However, 72% (n = 144; or 27% overall) of those eligible
did not consent. Almost half (n = 71; 13% overall) were re-
corded as “no reason given” for non-participation. The
trial manager identified these were often people needing
time to consider participation after screening but some re-
search facilitators were unable to contact patients by tele-
phone to complete consent. Research facilitators worked
during the day (when most participants were at work) and
not evenings, when patients could be more readily con-
tactable. The other half of patients (n = 73) not consenting
gave understandable reasons (see Fig. 1). Of these 12%
(n = 17) thought VR would interfere too much with their
work/ daily life and 23% (n = 33) did not want VR/work
advice. During the trial, the trial manager identified some
research facilitators were unclear about flexibility of the
VR and employer contact being unnecessary. To help
research facilitators allay patients concerns, further site
training was provided.
Overall, 63% (n = 340) were ineligible. Of these, 8%
(n = 41) of patients had incomplete screening. The trial
manager identified these were patients sent invitation
letters prior to clinics, added to the screening list but
some research facilitators were then unable to attend
clinic to complete screening in person or contact pa-
tients later by telephone.
Participants’ baseline characteristics
The two groups were well balanced at baseline across
most demographic, work and health measures (Tables 1
and 2). However, there were more people with level 3 and
4 jobs in the intervention group compared to level 2 jobs
in the control group (Table 1). The baseline RA-WIS
score was 15.7 (SD 5.3), with six having low (<10), 20
moderate (≥10 to <17) and 29 high (≥17) work instability.
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Fidelity of VR delivery
The monitoring visits confirmed occupational therapists
conducted assessments appropriately. The WES-RC re-
view indicated therapists identified a wide range of prob-
lems and provided appropriate treatment matching
problems. The commonest problems were: Preparing
for/getting to work (Getting ready in the morning,
n = 17) and Driving to work, n = 13); Physical Demands
(Standing too long, n = 14; Lifting/moving, n = 14);
Work/mental time demands (Concentrating, n = 12;
Work pace scheduling, n = 12). Matching solutions in-
cluded, respectively: advance planning, daily activities
and driving advice; pacing and moving and handling ad-
vice/ training; and fatigue management.
Feasibility of assessment methods
At baseline, most (n = 53) participants in both groups
correctly completed all questionnaire items, apart from
two (one in each group) having missing data in either
the output demands or time management demands
scales of the WLQ. At six and nine months, 44/55 and
43/55 respectively returned questionnaires (80% and
78% response rates: see Fig. 1). Within questionnaires,
75 to 80% of participants in both groups fully completed
measures. In the monthly absenteeism calendars, 80% in
both groups completed at least 70% of monthly forms.
For the EQ-5D and the resource questionnaire, used for
health economic analysis, it was feasible to collect the
required quality of life and cost data. We identified
Fig. 1 CONSORT flow diagram
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“rheumatology appointments” needed separating into
rheumatology consultant or nurse appointments, due to
differing costs.
Outcomes
At nine-month follow-up, for the intervention group,
changes in score from baseline corresponded to medium
effect sizes (+/− 0.5 to +/− 0.7) in the RA-WIS, WLQ
Summed and Productivity Loss scores, confidence in
managing arthritis at work, physical function (SF-12v2),
pain, hand pain and perceived health status (Tables 3
and 4). In comparison, there were smaller changes in
scores for the control group, corresponding to either no
or small effect sizes (Tables 3 and 4). Two participants
(both in the intervention group) were known to have
stopped working (one had already taken early retirement
before referral for VR). Similar numbers of people in
both groups had sickness absences at six and nine-
month follow-up, although the percentage of working
days lost was less in the intervention group at both time
points (Table 5). Satisfaction with work advice received
was higher in the intervention group (7.8 (SD 2.1)) ver-
sus 6.7 (SD 2.3) in the control group. No adverse events
were reported.
Participants in the intervention group attended on
average 2.86 (SD 1.55) VR sessions (n = 25 participants
attending VR). Direct VR lasted on average 3.92 (SD
1.61) hours and indirect VR was an additional 1.68 (SD
1.46) hours. The average cost per participant of VR was
£135.18 (SD £81.80) for occupational therapy staff time
and mileage costs.
Mean EQ-5D health state changes in scores from base-
line to six and nine months corresponded to small effect
sizes in the intervention group and none in the control
group (Tables 2, 3 and 4). For the EQ5D-3 L mean scores
were similar between groups: intervention was 0.56 (base-
line), 0.64 (6 months) and 0.56 (9 months) and control
group was 0.52 (baseline), 0.56 (6 months) and 0.57
(9 months). QALYS were −0.60 for the intervention group
and −0.56 for the control group, i.e. the intervention
Table 1 Baseline demographic characteristics (n = 55)
Characteristic Intervention (n = 29) Control (n = 26) Total (n = 55)
Age (years):Mean [sd] 47.7 [10.4] 50.5 [6.4] 49.0 [8.8]
Gender: Females n (%) 22 (75.9%) 20 (76.9%) 42 (76.4%)
Marital status:
Married/living with partner 24 (82.8%) 16 (61.5%) 40 (72.7%)
Other 5 (17.2%) 10 (38.5%) 15 (27.3%)
Living alone: n (%) 5 (17%) 9 (35%) 14 (25%)
Type of arthritis: n (%)
Inflammatory arthritis 5 (17.2%) 3 (11.5%) 8 (14.5%)
Rheumatoid arthritis 17 (58.6%) 17 (65.4%) 34 (61.8%)
Psoriatic arthritis 7 (24.1%) 6 (23.1%) 13 (23.6%)
Disease duration (years): Median [IQR] 5.0 [0.7–10.0] 5.3 [1.0–17.0] 5.0 [0.7–12.0]
Currently taking oral or intramuscular steroids: Yes n (%) 12 (41.4%) 7 (26.9%) 19 (34.5%)
Currently taking disease modifying drugs: Yes n (%) 26 (89.7%) 20 (76.9%) 46 (83.6%)
Currently taking biologic drugs: Yes n (%) 8 (27.6%) 9 (34.6%) 17 (30.9%)
Main job type (SOC2010 major group)*
Level 4 (Professional and managerial) 12 (41%) 3 (12%) 15 (27%)
Level 3 (Associated professional and technical/ skilled trades) 7 (24%) 1 (4%) 8 (16%)
Level 2 (Administrative, caring, leisure, sales, customer service;
process, plant and machinery operatives)
8 (28%) 21 (81%) 29 (53%)
Level 1 (Elementary occupations) 2 (7%) 1 (4%) 3 (5.5%)
Years in current main job: Mean [sd] 11.0 [8.9] 13.5 [9.7] 12.2 [9.3]
Full-time work (>35 h/week) n (%) 17 (58.6%) 16 (61.5%) 33 (60%)
Average hours worked/week: Mean[sd] 32 [9.1] 32.8 [8.7] 32.4 [8.8]
Disclosed arthritis to: Yes n (%)
Employer 25 [86.2%] 23 [88.5%] 48 [87.3%]
[At least some] Work colleagues 26 [90%] 23 [88.5%] 49 [90%]
Key: * SOC2010 = Standard Occupational Classification 2010 [56]
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group gained 0.05 more QALY than the control group.
Hospital resource use was similar at baseline, six and nine
months between the two groups, as was help from others
with home activities (see Additional file 1: Table S6).
Choice of primary outcome measure
Participants interviewed about the outcome measures
(n = 8) reported no difficulties completing presenteeism
or absenteeism measures and expressed no preference
for the most important to use. Completion rates were
better for presenteeism than absenteeism measures. The
three presenteeism measures (RA-WIS, WLQ, WALS)
had similar psychometric properties, correlated similarly
with other health and work measures and had similar
completion rates. Larger effect sizes were seen for the
WLQ Summed score and RA-WIS (i.e. +/− 0.7 at nine
months, see Table 4), suggesting these measures would
more likely detect differences in a trial. Very few stopped
working within the nine-month follow-up period
(n = 2), suggesting time to job loss and employment
status are not applicable outcomes unless a trial has a
long follow- up (e.g. four to five years).
Discussion
This feasibility trial demonstrated job retention VR was
credible, acceptable and deliverable to people with RA,
PsA or IA. The findings indicate VR may reduce risk of
job loss and improve productivity, confidence managing
arthritis at work, physical ability, pain and perceived
health. The control group remained largely unchanged.
Results should be interpreted with caution as this was a
feasibility trial, with small numbers and we did not
therefore conduct inferential testing.
We also conducted interviews with participants and the
occupational therapists to investigate their views of VR
and the work advice provided [30, 31]. Intervention group
participants valued the VR, particularly the training in
work-based pain and fatigue self-management, joint pro-
tection, pacing, ergonomic and job adaptations/ accom-
modations advice. They reported: relief from discussing
Table 2 Work and health related characteristics at baseline (n = 55)
Characteristic Intervention (n = 29) Control (n = 26) Total (n = 55)
RA-Work Instability Scale (0–23): Mean [sd] 16.2 [5.0] 15.0 [5.7] 15.7 [5.3]
Workplace Activity Limitations Scale (0–36): Mean [sd] 12.8 [5.3] 12.7 [6.2] 12.7 [5.7]
Workplace Limitations Questionnaire (0–100):
Productivity Loss: Mean [sd] 10.9 [4.9]
(n = 27)
11.2 [5.6]
(n = 24)
11.0 [5.2]
(n = 51)
Time management demands: Mean [sd] 52.1 [25.1]
(n = 28)
51.9 [28.9]
(n = 25)
52.0 [26.7]
(n = 53)
Physical demands: Mean [sd] 45.1 [23.4] 42.8 [23.1] 44.0 [23.1]
Mental/interpersonal demands: Mean [sd] 32.5 [21.8] 31.7 [24.4] 32.1 [22.8]
Output demands: Mean [sd] 40.0 [27.5]
(n = 28)
41.0 [28.0]
(n = 25)
40.5 [27.5]
(n = 53)
WLQ Summed: Mean [sd] 43.0 [18.2]
(n = 27)
43.9 [20.1]
(n = 24)
43.4 [18.9]
(n = 51)
Work Self-Efficacy: Mean[sd] (0–10) 7.0 [2.4] 7.2 [2.2] 7.1 [2.1]
Confidence managing arthritis at work: Mean[sd] (0–10) 4.6 [2.7] 5.7 [2.4] 5.1 [2.6]
SF12v2 Health Survey (0–100):
Physical component: Mean [sd] 32.5 [8.3] 32.6 [10.1] 32.5 [9.1]
Mental component: Mean [sd] 40.1 [10.9] 42.4 [12.4] 41.2 [11.6]
Multidimensional Health Assessment Questionnaire (0–3):
Functional status: Mean [sd] 0.6 [0.4] 0.7 [0.5] 0.7 [0.5]
Psychological status: Mean [sd] 1.0 [0.6] 0.9 [0.7] 1.0 [0.7]
Pain VAS (0–100): Mean [sd] 50.4 [22.6] 45.7 [25.7] 48.2 [24]
Hand Pain VAS (0–100): Mean [sd] 51.8 [26.4] 51.3 [27.3] 51.6 [26.6]
Fatigue VAS (0–100): Mean [sd] 60.0 [22.4] 58.7 [30.1] 59.4 [26.1]
Perceived Health Status VAS (0–100): Mean [sd] 50.9 [18.4] 48.7 [23.1] 49.9 [20.6]
EQ5D VAS Health State mean [sd] 55.7 [16.9] 61.0 [18.7] 58.2 [17.8]
Key: For all variables higher scores indicate worse work/health status, apart from work self-efficacy where higher scores indicate increased confidence and SF12v2
measures where higher scores indicate better health status
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work problems with the occupational therapists; making
behavioural adaptations at work; and improved coping
skills [30]. In contrast, the control group discussed the
continuing negative impact of arthritis on their work and
feeling anxious about continuing working in future. Most
participants in both groups had either not read the self-
help work information or considered it had little impact
[30]. The occupational therapists considered: the VR was
beneficial for patients; and they could now provide a more
comprehensive and individualised VR service [31].
The positive quantitative and qualitative findings
suggest this VR intervention is promising. Healthy work
has positive health benefits [32, 33]. People with health
conditions who lose their job can struggle to get back to
work, have financial difficulties, reduced retirement pen-
sions, loss of positive psychological and social support
from working, reduced wellbeing and worse health.
Employers lose valuable skills and health services bear
additional costs [34]. Forced retirement at 65 years of
age no longer exists, the UK state pension age is rising
and many people will need to work for longer. Initiatives
supporting helping people with arthritis stay in work for
longer are of benefit to both employees and employers.
Direct VR averaged under four hours and the total cost
was £135/ participant (including indirect VR). If job
retention VR is proven effective in an RCT, this is a
Table 3 Work and health related outcomes at six and nine months from questionnaires
Outcome Six months Nine months
Intervention (n = 23) Control (n = 21) Intervention (n = 22) Control (n = 21)
RA-Work Instability Scale (0–23): Mean [sd] 13.1 [6.3]
(n = 22)
15.5 [5.8]
(n = 21)
12.3 [7.8]
(n = 21)
14 [6.2]
(n = 21)
Workplace Activity Limitations Scale (0–36): Mean [sd] 10.7 [6.5]
(n = 22)
13.2 [6.4]
(n = 21)
10.4 [6.8]
(n = 21)
13.5 [9.0]
(n = 21)
Workplace Limitations Questionnaire (0–100):
Productivity Loss: Mean [sd] 9.3 [5.8]
(n = 21)
10.3 [4.6]
(n = 19)
7.5 [5.3]
(n = 20)
9.3 [6.3]
(n = 20)
Time management demands: Mean [sd] 39.3 [29.6]
(n = 22)
47.1 [22.8]
(n = 19)
33.3 [26.1]
(n = 21)
41.8 [28.4]
(n = 20)
Physical demands: Mean [sd] 36.6 [18.6]
(n = 22)
46.3 [24.5]
(n = 21)
35.7 [26.9]
(n = 20)
37 [18.9]
(n = 21)
Mental/interpersonal demands: Mean [sd] 31.5 [23.2]
(n = 22)
32.5 [18]
(n = 20)
25.8 [20.1]
(n = 21)
28.5 [23.4]
(n = 21)
Output demands: Mean [sd] 36 [28]
(n = 21)
41.3 [24.6]
(n = 20)
25.2 [23.3]
(n = 21)
38.5 [32.2]
(n = 21)
WLQ Summed: Mean [sd] 35.4 [21.1]
(n = 21)
41.3 [18.1]
(n = 19)
29.8 [19.7]
(n = 20)
35.9 [21.5]
(n = 20)
Work Self-Efficacy: Mean[sd] (0–10) 7.6 [2.2]
(n = 22)
6.5 [2.8]
(n = 21)
7.8 [2.1]
(n = 21)
6.5 [2.2]
(n = 21)
Confidence managing arthritis at work: Mean[sd] (0–10) 7.1 [2.5]
(n = 22)
6.1 [2.7]
(n = 21)
7.5 [2.1]
(n = 21)
6.4 [2.6]
(n = 21)
SF12v2 Health Survey (0–100):
Physical component: Mean [sd] 37.7 [10.1] 32.4 [10.6] 38.7 [10.5] 34.3 [10.9]
Mental component: Mean [sd] 41.3 [12.8] 42 [9.5] 41.6 [12.5] 44.2 [11.4]
Multidimensional Health Assessment Questionnaire (0–3):
Functional status: Mean [sd] 0.6 [0.5] 0.8 [0.5] 0.6 [0.6] 0.7 [0.6]
Psychological status: Mean [sd] 0.9 [0.7] 1.0 [0.5] 0.9 [0.7] 0.9 [0.6]
Pain VAS (0–100): Mean [sd] 43.1 [27.1] 48.5 [27.3] 40.5 [27.6] 44.1 [27.0]
Hand Pain VAS (0–100): Mean [sd] 43.0 [31.0] 52 [28.9] 39.8 [30.1] 52.3 [27.1]
Fatigue VAS (0–100): Mean [sd] 54.4 [30.2] 57.7 [21.9] 54.3 [33.3] 58.7 [23.8]
Perceived Health Status VAS (0–100): Mean [sd] 41 [26.5] 52 [22.2] 38.5 [25.2] 44.2 [23.7]
EQ5D VAS Health State mean [sd] 63.2 [23.4] 63.1 [20.1] 59.1 [26.0] 60.4 [22.4]
Key: For all variables, higher scores indicate worse work/health status, apart from work self-efficacy where higher scores indicate increased confidence and SF12v2
measures where higher scores indicate better health status
One participant in the intervention group who returned the questionnaire booklets stopped working during the 6-month follow-up period and did not complete
the presenteeism outcomes at either timepoint. At nine months, pain, hand pain, fatigue and perceived health status VAS were not completed by one participant
in the control group, who returned the questionnaire
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relatively low cost for a potentially large saving to people
with arthritis, the NHS, employers and society. In future,
employer insurance could potentially pay for such ser-
vices from the NHS.
The study built on previous successful job retention
VR research [10], whilst making VR pragmatic and de-
liverable in a UK NHS setting. The intervention was
individualised, flexible and spread over several months
to allow participants time to make changes between
sessions and reduce the impact of taking time out of
work. The resource use questionnaire identified how
frequently many patients have to attend other appoint-
ments, highlighting the need for flexible VR and mini-
mising disruption to patients’ work schedules.
Whilst workplace visits are beneficial [35], we decided
to make them optional as these can only be undertaken
if the person has disclosed their condition to their em-
ployer and agrees to them. Accordingly, the benefits of
disclosure, employer liaison and workplace visits were
discussed during VR, as relevant. Only three work visits
were undertaken. Most participants either did not want
a workplace visit, or felt confident to address job accom-
modation needs with employers and a visit was not es-
sential, which also helped reduce costs. Relatively few
participants agreed to employer contact for interviews.
We had anticipated higher levels of workplace engage-
ment as national guidelines recommend a workplace
component [36]. The occupational therapists delivered
VR in less than the planned time and budget, with re-
sults indicating improvements in outcomes. Accordingly,
providing job retention VR in these Rheumatology occu-
pational therapy services was feasible. The control group
only received written advice (reflective of that provided
to many with arthritis). As no or only small effects were
seen in work and health outcomes in the control group,
written advice was an appropriate control intervention.
Of the candidate primary outcome measures, the ab-
senteeism measure (monthly calendar) provided detailed
data but completion rates were lower than for presentee-
ism and had too high a responder burden. Three
monthly self-report of sick leave days (with average
number of days normally worked per week) would be
less onerous and could lead to better response rates. The
WLQ and RA-WIS presenteeism measures are consid-
ered the best options. The Outcome Measurement in
RA Clinical Trials (OMERACT) Work Group previously
had identified the WLQ, WALS and RA-WIS as present-
eeism measures [37, 38]. However, subsequently they de-
termined the RA-WIS is not a presenteeism measure,
although still important as a prognostic measure [39], as
scores >11 are predictive of future reduction in work
hours and >13 of disability leave of absence [39]. Ac-
cordingly, the WLQ is the most applicable primary out-
come for an RCT. Presenteeism has the greatest impact
on costs for people with RA [40], confirming the rele-
vance of this. Sample sizes of 120 to 140 would be re-
quired for a definitive RCT with 90% power, two-sided
5% significance level and allowing for a 20% loss to
follow-up, using published data on minimum clinically
important differences for these presenteeism outcomes
[21, 41, 42] and using the standard deviations observed
in this feasibility trial.
Only 20% of people with RA consider they receive suffi-
cient information and practical support about employment
Table 5 Employment status and absenteeism at six and nine months (n = 55)
Characteristic Six months:
Intervention (n = 23)
Six months:
Control (n = 21)
Nine months:
Intervention (n = 22)
Nine months:
Control (n = 21)
Employment status:
Working full time 15 11 13 11
Working part-time 7 8 7 8
On sick leave 0 2 0 2
Stopped working 1 0 2 0
Sickness absence: n =24 n =21 n =21 n =19
Sickness absence any
reason (no.):
18 (75%) 16 (76.2%) 17 (81.1%) 16 (84.2%)
Sickness absence due
to arthritis (no.)
12 (50%) 13 (61.9%) 14 (66.7%) 14 (70.0%)
Percentage working days lost
due to sickness
(any reason): Mean [SD]
8.4 [11.7] 18.6 [25.8] 9.6 [13.6] 20 [27.1]
Median [IQR] 3.1 [0.5-10.7] 8.2 [2.8-33.6] 4.4[ 0.7-13.1] 8.3 [2.1-29.3]
Percentage working days lost
due to arthritis:Mean [SD]
5.5 [11.2] 12.4 [23.6] 8.0 [13.8] 15.0 [25.0]
Median [IQR] 0.5 [0-4.4] 3.5 [0-9.1] 2.5 [0-7.9] 5 [0-21.4]
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issues from their Rheumatology service [1]. Many em-
ployees with arthritis are unaware of job retention VR ser-
vices available and provision of these is patchy in the UK.
VR is currently available from: occupational health depart-
ments, usually only available in larger organisations, but
60% of employees work for small to medium sized enter-
prises; the “Fit for Work Service,” although referral to an
occupational health professional is made only when an em-
ployee has been off sick for four weeks or more (before
then self-help internet advice and telephone support are
available) [43]; the Access to Work scheme, which the per-
son applies for themselves, can provide grants for job ac-
commodations (e.g. transport, equipment at work) [44];
and Job Centre Disability Employment Advisors, although
services are primarily for the unemployed. NHS occupa-
tional therapists, with additional VR training, are well-
placed to provide early job retention VR. Occupational ana-
lysis and therapeutic interventions in the workplace are a
core part of occupational therapy practice [45]. Employed
people with inflammatory arthritis experiencing work prob-
lems, can be readily identified when patients attend
Rheumatology out-patients and referrals made to occupa-
tional therapy. NHS-based VR means it is also available to
those who have not disclosed or do not want employer
contact. This job retention VR could also be applicable for
a wider range of rheumatological conditions.
During the study, some research facilitators highlighted
patients, particularly in areas with higher social deprivation
and in precarious employment, expressed concerns about
taking time out of work and/ or did not want VR, influen-
cing their non-participation. The British Society of
Rheumatology is now supporting training for Rheumatol-
ogy teams to have “work conversations” with patients to
promote the importance of staying working and obtaining
work advice. In a future trial, ensuring teams have training
in, and implement work conversations, could prime pa-
tients to perceive VR as important to receive.
There were limitations in this study. The two groups
differed in occupational groupings and, in a definitive
RCT, trial stratification by occupational group (levels 1
to 4) would reduce this disparity. The recruitment time
was nearly half that planned, partly due to the time
obtaining R&D approvals. The NHS Health Research
Authority has since streamlined approvals processes,
with targets for completions and recruitment. Our re-
cruitment strategy was screening in two Rheumatology
clinics per week. However, limited research facilitator
availability caused delays in sites starting, periods of no
screening and early site closure. Only 10% of patients
screened were randomised into the study. This was how-
ever, consistent with pre-trial predictions. A two-week
audit before the trial at one site identified 25% of
Rheumatology out-patients were employed people with
RA, PsA or IA. Studies evaluating RA-WIS scores in
employed people with RA identified 34 to 69% had
scores ≥10%, i.e. moderate to high risk of work disability
[11, 46–49]. We estimated nine to 18% of Rheumatology
out-patients could meet key eligibility criteria, but that
the other criteria and unwillingness to participate would
reduce recruitment to 10% or less of out-patients.
Research facilitators had problems contacting up to
20% of those identified to complete screening or con-
sent. Research facilitators worked only during the day
and often only had patients’ home landline telephone
numbers and not work/ mobile telephone numbers and
e-mail addresses. This prevented contacting employed
patients in the evenings. It is clearly important to ensure
a range of contact details are obtained at the point of
first contact with potential participants. In consequence,
in a future trial, employing a research fellow, working
flexibly into some evenings, would assist contacting pa-
tients outside normal work hours. The research fellow
can then complete screening and consent by telephone
with patients, ensure baseline questionnaires are sent
out/returned and patients randomised (subject to pa-
tients’ permission for contact details to be forwarded).
When research facilitators are unavailable to complete
screening and recruitment, a research fellow can also
complete study procedures. To increase numbers of people
with RA, PsA or IA referred for screening, working age/
employed patients could be identified by healthcare team
members/ research facilitators from department data-
bases, medical and therapy notes and in therapy de-
partments. Such patients could be mailed invitation
packs by research facilitators, with interested patients
returning a reply form to the research fellow who
completes study procedures.
Whilst an 80% retention rate is suggested as near the
limit of validity for RCTs [50], our 20% attrition was
similar to other job retention VR trials [10, 51] and
other RA rehabilitation trials e.g. [52, 53]. This retention
rate may reflect the more adherent, motivated group of
people choosing to participate and willing to commit the
time, which arguably reflects the situation in every trial.
The trial manager contacted participants by telephone in
the evenings to give questionnaire reminders to promote
retention. A research fellow could also contact partici-
pants, day and evenings, to assist questionnaire comple-
tion and obtain a minimal data set, when necessary.
Additional retention strategies could be considered, such
as advance postcards and text reminders indicating
questionnaires will be sent shortly, a second question-
naire reminder and using financial rewards or incentives
[54, 55]. We had many measures in the questionnaire, as
an aim was to identify the most applicable primary work
outcome measure. Accordingly, responder burden would
be reduced in a definitive trial, which may encourage
better completion.
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Conclusion
The findings from this study suggest job retention VR
provided by NHS occupational therapists with VR train-
ing is credible, acceptable, deliverable and promising for
employed people with arthritis with concerns about con-
tinuing to work in future because of their condition. The
finding regarding screening and recruitment suggest re-
cruitment could be challenging and requires additional
research fellow support. Consideration needs to be given
to the number needing to be screened (around 1350) to
achieve the recruitment target, the number of sites and
length of recruitment period required to achieve the tar-
get. There is a need for a definitive trial of this brief job
retention VR in the UK, with the caveat of ensuring
sufficient funding for out-of-hours and remote screen-
ing, recruitment and retention support to ensure timely
recruitment and maximised response rates.
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